Adimab Amends Invivyd Stake, Signals Ownership Change
Ticker: IVVD · Form: SC 13D/A · Filed: Jan 22, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | SC 13D/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $3.95 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, amendment, institutional-investor
TL;DR
**Adimab just updated its Invivyd stake, watch for potential stock movement.**
AI Summary
Adimab, LLC, a significant shareholder in Invivyd, Inc., filed an amended Schedule 13D on January 22, 2024, indicating a change in their beneficial ownership. This Amendment No. 3 filing updates previous disclosures regarding Adimab's stake in Invivyd's Common Stock, $0.0001 par value per share. This matters to investors because changes in large institutional holdings can signal shifts in confidence or strategic intent, potentially influencing stock price and future corporate actions for Invivyd.
Why It Matters
This filing updates the public record on a major shareholder's position, which can influence investor sentiment and potentially impact Invivyd's stock valuation.
Risk Assessment
Risk Level: medium — Changes in significant shareholder positions can introduce volatility and uncertainty regarding a company's future direction.
Analyst Insight
Investors should monitor subsequent filings from Adimab, LLC and Invivyd, Inc. for further details on the nature of this ownership change and any potential strategic implications.
Key Players & Entities
- Adimab, LLC (company) — the reporting person and significant shareholder of Invivyd, Inc.
- Invivyd, Inc. (company) — the subject company whose securities are being reported on.
- Philip Chase (person) — the person authorized to receive notices and communications for Adimab, LLC.
- $0.0001 (dollar_amount) — the par value per share of Invivyd's Common Stock.
- January 19, 2024 (date) — the date of the event which required the filing of this statement.
Forward-Looking Statements
- Adimab, LLC may be adjusting its strategic involvement with Invivyd, Inc. following this ownership update. (Adimab, LLC) — medium confidence, target: Q2 2024
FAQ
What is the purpose of this SC 13D/A filing?
This SC 13D/A filing is an Amendment No. 3 to a previous Schedule 13D, indicating an update or change in the beneficial ownership of Invivyd, Inc. Common Stock by Adimab, LLC, as required by the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person in this filing is Adimab, LLC, located at 7 Lucent Drive, Lebanon, NH 03766.
What is the subject company whose securities are being reported on?
The subject company is Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., with its business address at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock, $0.0001 par value per share, of Invivyd, Inc. is 00534A102.
When was the event that triggered this filing?
The date of the event which required the filing of this statement was January 19, 2024.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-01-22 16:15:49
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
- $3.95 — Act of 1933, as amended, at a price of $3.95 per share. Except as set forth above, n
Filing Documents
- d615807dsc13da.htm (SC 13D/A) — 31KB
- 0001193125-24-012170.txt ( ) — 33KB
of the Schedule 13D is hereby supplemented as follows
Item 1 of the Schedule 13D is hereby supplemented as follows: On September 9, 2022, Invivyd, Inc. (the Issuer ) filed a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware solely to change the Issuers name from Adagio Therapeutics, Inc. to Invivyd, Inc. The name change became effective on September 13, 2022. Item 5. Interest in Securities of the Issuer.
(a), Item 5(b) and Item 5(c) of the Schedule 13D are hereby amended as follows
Item 5(a), Item 5(b) and Item 5(c) of the Schedule 13D are hereby amended as follows: (a) (b) Amount beneficially owned: 21,687,906 Percent of Class: 19.7% Number of shares the Reporting Person has: Sole power to vote or direct the vote: 21,687,906 Shared power to vote: 0 Sole power to dispose or direct the disposition of: 21,687,906 Shared power to dispose or direct the disposition of: 0 The above percentage is based on 110,114,960 shares of Common Stock outstanding as of November 2, 2023, as reported in the Issuers Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. (c) On January 19, 2024, the Reporting Person sold 5,000,000 shares of Common Stock pursuant to Rule 144 under the Securities Act of 1933, as amended, at a price of $3.95 per share. Except as set forth above, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the Related Persons or other individuals named in Item 2 of the Schedule 13D, has effected any transaction in shares of Common Stock during the past 60 days. CUSIP No. 00534A102 13D Page 3 of 3 pages
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : January 22, 2024 Adimab, LLC By: /s/ Philip Chase Name: Philip Chase Title: Chief Executive Officer